HHorinouchi· @HHorinouchi · X·· 2 days agoScore60
Body · original
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥KANDLELIT-001: Calderasib (MK-1084), Alone or in Combination, for KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer (mNSCLC) 🎙️ @nahit_sendur 🔢2680RO 🎯With Pembrolizumab (PD-L1 TPS≥1%): ORR 72%, Median PFS 28.9mo (n=98); TPS≥50% ORR 87%; 🎯Monotherapy ORR 27%; Calderasib+Pembro+Chemo ORR 65%, PFS 15.1mo ☑️NCT05067283 🔗 https://t.co/p4tFUd6NwV @OncoAlert @Larvol @myESMO @IASLC @KRASKickers
Heat 12 · 8 likes · 0 replies · 4 reposts
Conference abstracts
NCT05067283NCT05067283matched by - **标题 / Title：** A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- **标题 / Title：** A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)Read the abstract →Source: HHorinouchi · x.com